Romosozumab Benefits Sustained After Transition to DenosumabRomosozumab Benefits Sustained After Transition to Denosumab

Improvements previously seen in 1 year data on the antisclerostin antibody continue with 2 years of treatment and with transition to denosumab in year 3. Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news